Skip to content
Medical Health Aged Care

Optometrists keep an eye on heart health

For immediate release - September 28, 2023 2 mins read

With 2023 research suggesting 66 per cent of people susceptible to heart disease are unaware they are at risk, new optometry technology is breaking ground in the detection of potential heart issues through the power of Artificial Intelligence (AI).

As a means of bridging the gap between eye care and general health care, Bupa Optical’s Microvascular Health Assessment uses AI technology to detect underlying health problems and help customers better understand whether they are at risk of developing cardiovascular disease.

To date, the Microvascular Health Assessment has graded three per cent of customers whose heart health risk rating has been assessed by the tool as ‘poor’ with Bupa optometrists subsequently advising them to see their doctor for possible further tests and discussions before many knew they may have a health issue.

Guneet Sawhney, Director Bupa Optical & Hearing said the test compares a patient’s eyes with a database of retinal images in a matter of seconds to check for similarities to other conditions that may be a signs of a potential heart issue through a detailed report.

“The eye is a window into the heart and the only place in the body where people can get a direct, non-invasive view of a person’s blood vessels which can tell a broad story about an individual’s current and future health risks,” Guneet said.

“Through our Microvascular Health Assessment tool, we’re extending routine eye tests into broader non-invasive health checks which can be referred to a medical professional if any red flags come up. This makes heart health monitoring more accessible for everyday Australians.”

This advice is being reinforced in the lead-up to World Heart Day aimed at promoting better heart health practices such as eating better, exercising more and regularly monitoring your health. Around the world cardiovascular disease kills more than 20.5 million people every year and accounts for one in four Australian deaths.  

“We truly believe this technology, which is available as an add-on to a standard eye test, can help customers better understand their underlying heart health,” Guneet said.

For more information or to book an eye test at your nearest Bupa Optical store visit here



Please contact:

Eli Grynberg

External Communications Manager, Bupa

Mob: 0401 135 713



More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.